New support tool aims to ease bladder cancer care burden
NCT ID NCT06414317
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a special education and navigation program for people with advanced bladder cancer and their caregivers. The program provides guidance, nutritional advice, and distress screening to help them better manage treatment decisions and care coordination. Researchers hope this support tool will improve how patients and caregivers participate in care planning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Education and Navigation Support Tool (ENST)
- What this could lead to
- If successful, this program could help patients and caregivers feel more in control and better coordinate care for advanced bladder cancer.
- What could go wrong
- This is a small, early-stage study focused on support, not a treatment. It may not show clear benefits or be widely applicable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody-drug combo tackle rare bladder cancers?
- New cocktail of drugs takes on Hard-to-Treat bladder cancer
- New strategy aims to eliminate residual bladder cancer after drug combo
- New hope for bladder cancer patients who Can't take chemo
- Experimental triple therapy for advanced cancers shows early promise but trial halted
- New hope for advanced bladder cancer? drug targets specific gene mutations